Dr. John B. Buse, MD

Dr. Buse practices at UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System.

Dr. Buse's NPI, 1336164680, was assigned on July 13, 2006. Dr. Buse graduated from Duke University School Of Medicine in 1986. Dr. Buse's North Carolina license number on file is 9400739.

Dr. Buse's primary practice is UNC Hospitals, at 101 Manning Drive, Chapel Hill, NC 27514 in Orange County. The practice phone is (919) 966-4141.

Dr. Buse's primary practice is UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System. The medical group on file is UNC Faculty Physicians. Dmand AI also links Dr. Buse to 1 more therapy and rehab clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Buse practices, 2 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Buse's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Buse is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dmand AI has Dr. Buse's licenses on file in 2 states: North Carolina and Illinois.

Dmand AI lists chronic diabetes, diabetic emergency, obesity, osteoporosis and vitamin b deficiency among the conditions Dr. Buse treats.

CMS data shows 235 Medicare services from Dr. Buse across 3 procedure codes in 2024, for 56 Medicare patients. Medicare paid $9,975 for them. Every service was in an office.

CMS counts 56 Medicare patients who saw Dr. Buse in 2024. The largest group is 75 to 84, with 24 patients. 75% of them have diabetes, and 75% have high blood pressure. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Buse's median patient age at 76, with 46% women.

In 2024, Dr. Buse wrote 1,530 Medicare Part D claims for 103 patients. 58% of them were for generic drugs. CMS names the drug for 1,221 of them, across 38 drugs with 11 or more claims each, at $523,929 in total drug cost. In 2023, CMS named 1,201 claims across 33 drugs.

Dr. Buse accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Buse as offering telehealth.

Dmand AI links 426 papers to Dr. Buse, published from 2006 to 2025. 2019 was the busiest year, with 31. The most frequent topics are Diabetes Mellitus, Type 2, Hypoglycemic Agents and Blood Glucose. Dr. Buse has published most often in Diabetes Care. Dr. Buse's most frequent co-authors are Richard Edwin Pratley, MD, Darren Keith McGuire, MD and Klara R. Klein, MD, PhD.

Dmand AI links Dr. Buse to 7 clinical trials. Conditions studied include Diabetes Mellitus, Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1. University of North Carolina, Chapel Hill sponsors the most, 2. Open Payments lists research payments to Dr. Buse that name 1 trial.

CMS Open Payments shows 491 general payments to Dr. Buse from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Novo Nordisk AS paid the most, $313,939. It also lists 19 research payments totaling $9,659 from 2017 to 2025, naming 1 clinical trial.

Dmand AI lists 26 awards for Dr. Buse, most recently America's Top Doctors in 2019. Dr. Buse serves on member CTSA Program Steering Committee.

Dr. Buse graduated from Duke University School Of Medicine in 1986. Dr. Buse is a member of ADA.

Dr. Buse is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.